Skip to content
Review

Targeting Klotho Signaling for Neuroprotection in Huntington's Disease: A Comprehensive Review.

Aug 2026 · Current molecular medicine · 0 citations
Medicine

TL;DR

Klotho is a promising neurochemical modulator with disease-modifying properties in HD, and its multifunctional protective activities are consistent with important pathological markers of HD, necessitating more preclinical and clinical studies to confirm its translational value.

Abstract

INTRODUCTION HD is a hereditary neurodegenerative disease caused by the amplification of the CAG trinucleotide repeat in the HTT gene, leading to a Mutant Huntingtin (mHTT) protein that dysregulates transcription, promotes protein aggregation, induces neuroinflammation, and impairs mitochondrial function. Motor dysfunction, cognitive decline, and mental disorders are manifestations of these biochemical abnormalities. Effective disease-modifying treatments are still limited, even with recent improvements. This review investigates the increasing relevance of Klotho, an anti-aging protein with neuroprotective, antioxidant, and anti-inflammatory characteristics, as a possible therapeutic target in Huntington disease.

Methods

We did a comprehensive literature search across PubMed, Scopus, and Web of Science databases. Klotho's molecular functions in neural protection, energy metabolism, oxidative stress reduction, and anti-inflammatory signalling were investigated in the context of HD pathogenesis.

Results

Klotho appears to influence critical neurodegenerative processes involved in HD. It inhibits NF-κB and NLRP3 inflammasome activity, stimulates antioxidant enzyme expression (SOD, catalase), promotes GluN2B-NMDA receptor-mediated synaptic plasticity, and increases astrocytic aerobic glycolysis via FGFR1-ERK signaling. These functions may mitigate mHTT- induced neuronal damage. Pharmacologic treatments (e.g., PPAR-γ agonists), vitamin D, and lifestyle interventions can all modulate klotho expression.

Discussion

Klotho exhibits neuroprotective effects in Huntington's disease by reducing NF-κB/NLRP3- mediated inflammation, strengthening antioxidant defenses, promoting GluN2B-NMDA- dependent synaptic plasticity, and improving astrocytic metabolic support via FGFR1-ERK signaling. One intriguing treatment approach for mutant huntingtin-induced neurotoxicity is the modification of klotho expression.

Conclusion

Klotho is a promising neurochemical modulator with disease-modifying properties in HD. Its multifunctional protective activities are consistent with important pathological markers of HD, necessitating more preclinical and clinical studies to confirm its translational value.

View source

Similar papers

Review Aug 2026

The potential of vitamins in Huntington’s disease: bridging mechanistic evidence with translational limitations and future strategies

How the vitamins’ potential is at stake to reach the clinical perspective is highlighted, along with different strategies to overcome their limitations using novel drug delivery and biomarker-based approaches.

V. Padole, Yogesh A. Kulkarni · 0 citations
Review Open access Aug 2026

Neurodegenaration: Overview

This review summarizes the major causes of neurodegeneration, recent developments in advanced cell-based in vitro models, and commonly employed neuroprotective assays, highlighting their importance in the discovery of novel therapeutic agents for neurodegenerative diseases.

D. A. Helen Sheeba, J. R, J. K et al. · 0 citations
Review Sep 2026

Designing Multi-functional Antioxidants for Neurodegenerative Disorders.

This review critically examines OS-mediated mechanisms underlying major NDs and emphasizes the therapeutic potential of designed multi-functional antioxidants as next-generation neuroprotective agents.

Kuleshwar Sahu, Rakesh Sahu, Mahima Mishra et al. · 0 citations
Review Sep 2026

Uncovering hidden protein networks in Huntington’s disease: implications for pathogenesis and therapy

Investigations using various experimental techniques reveal that faulty neuroplasticity develops before the formation of visible protein aggregates, leading to synaptic dysfunction and specific loss of striatal medium spiny neurons in Huntington’s Disease.

Chhavi Panwar, Falguni Goel, Vipin Kumar Garg · 0 citations
Review Open access Sep 2026

Targeted modulation of NF-κB1 in neurodegenerative diseases

Neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis, are characterized by progressive neuronal dysfunction and loss driven by convergent pathological mechanisms such as oxidative stress, mitochondrial impairment, protein misfolding, apo...

Priyanka Banerjee, Rakesh Das, Amartya Sen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.